Very interesting article! Cost Effectiveness of Ventricular Tachycardia Ablation Versus Escalation of Antiarrhythmic Drug Therapy: The VANISH Trial. The article contributes to foster #VT_ablations in spite of its complexity. https://t.co/7ULg519Zje
RT @miguel_a_arias_: ¿Es coste-efectiva la ablación de Taquicardia Ventricular en pacientes con Cardiopatía Estructural respecto al uso de…
RT @miguel_a_arias_: ¿Es coste-efectiva la ablación de Taquicardia Ventricular en pacientes con Cardiopatía Estructural respecto al uso de…
RT @JACCJournals: In the setting of VT secondary to #cvMI & refractory to AAD as initial therapy, ablation is cost-effective, compared to e…
RT @JACCJournals: In the setting of VT secondary to #cvMI & refractory to AAD as initial therapy, ablation is cost-effective, compared to e…
RT @JACCJournals: In the setting of VT secondary to #cvMI & refractory to AAD as initial therapy, ablation is cost-effective, compared to e…
RT @JACCJournals: In the setting of VT secondary to #cvMI & refractory to AAD as initial therapy, ablation is cost-effective, compared to e…
RT @JACCJournals: In the setting of VT secondary to #cvMI & refractory to AAD as initial therapy, ablation is cost-effective, compared to e…
RT @JACCJournals: In the setting of VT secondary to #cvMI & refractory to AAD as initial therapy, ablation is cost-effective, compared to e…
In the setting of VT secondary to #cvMI & refractory to AAD as initial therapy, ablation is cost-effective, compared to escalation of drug therapy: https://t.co/HUz21wN6EF. #JACCCEP #ablateVT https://t.co/zafnNK6HLg
RT @JACCJournals: In the setting of VT secondary to #MI & refractory to AAD as initial therapy, ablation is cost-effective, compared to esc…
RT @JACCJournals: In the setting of VT secondary to #MI & refractory to AAD as initial therapy, ablation is cost-effective, compared to esc…
RT @JACCJournals: In the setting of VT secondary to #MI & refractory to AAD as initial therapy, ablation is cost-effective, compared to esc…
RT @JACCJournals: In the setting of VT secondary to #MI & refractory to AAD as initial therapy, ablation is cost-effective, compared to esc…
RT @JACCJournals: In the setting of VT secondary to #MI & refractory to AAD as initial therapy, ablation is cost-effective, compared to esc…
RT @JACCJournals: In the setting of VT secondary to #MI & refractory to AAD as initial therapy, ablation is cost-effective, compared to esc…
For those failing Amlo only it appears https://t.co/KnJBJQzcax
RT @JACCJournals: In the setting of VT secondary to #MI & refractory to AAD as initial therapy, ablation is cost-effective, compared to esc…
RT @JACCJournals: In the setting of VT secondary to #MI & refractory to AAD as initial therapy, ablation is cost-effective, compared to esc…
RT @JACCJournals: In the setting of VT secondary to #MI & refractory to AAD as initial therapy, ablation is cost-effective, compared to esc…
RT @JACCJournals: In the setting of VT secondary to #MI & refractory to AAD as initial therapy, ablation is cost-effective, compared to esc…
RT @JACCJournals: In the setting of VT secondary to #MI & refractory to AAD as initial therapy, ablation is cost-effective, compared to esc…
RT @JACCJournals: In the setting of VT secondary to #MI & refractory to AAD as initial therapy, ablation is cost-effective, compared to esc…
In the setting of VT secondary to #MI & refractory to AAD as initial therapy, ablation is cost-effective, compared to escalation of drug therapy: https://t.co/ipm6nXfD3o. #JACCCEP #ablateVT @DalScience https://t.co/u3izHxfPoB
RT @maapalomares: ¿Es coste-efectiva la ablación de Taquicardia Ventricular en pacientes con Cardiopatía Estructural respecto al uso de fár…
RT @maapalomares: ¿Es coste-efectiva la ablación de Taquicardia Ventricular en pacientes con Cardiopatía Estructural respecto al uso de fár…
RT @maapalomares: ¿Es coste-efectiva la ablación de Taquicardia Ventricular en pacientes con Cardiopatía Estructural respecto al uso de fár…
RT @maapalomares: ¿Es coste-efectiva la ablación de Taquicardia Ventricular en pacientes con Cardiopatía Estructural respecto al uso de fár…
¿Es coste-efectiva la ablación de Taquicardia Ventricular en pacientes con Cardiopatía Estructural respecto al uso de fármacos antiarrítmicos? Datos del Estudio VANISH https://t.co/QSfxfu2LSS @secardiologia @blogarritmias @LuigiDiBiaseMD @Arritmias_H12O @R
VT ablation is better than escalated drug therapy in refractory VT in patients with ischemic CMP https://t.co/Hmn78GsCB5
Cost Effectiveness of Ventricular Tachycardia Ablation Versus Escalation of Antiarrhythmic Drug Therapy https://t.co/KnJM0JWI43